fr   en

Browse by date
Or search by keyword
Date: 2010-09-03
Company: Lumavita (Switzerland)
Amount: 11m (€8m)
Planned use: Lumavita AG, the Basel biopharmaceutical company specializing in novel anti-infectives for Women’s Health has raised approximately CHF 11m (€8m) from its current investors. T
his financing will enable the company to continue the development of its two products LMV-601 and LMV-602, and in particular will allow the completion of some first proof-of-concept studies in human in 2011.